Dupixent Injury Lawsuits Against Sanofi Consolidated in Federal Court in New Jersey
As of June 2026, more than a dozen lawsuits alleging that Sanofi’s “domestic blockbuster” eczema drug Dupixent (dupilumab) had dangerous and even deadly side-effects, including cutaneous T-cell lymphoma (CTCL), have been consolidated in federal court in New Jersey. Lieff Cabraser and other law firms are pursuing damages claims in the litigation in connection with its